Cipla Forms Joint Venture Company With Chinese Firm For Biosimilars Foray
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company
You may also be interested in...
Made In China, Sold In India: Cipla’s First Splash In Biosimilars Is A Cut Price Version Of Enbrel
The homegrown Indian drug manufacturer will sell its drug 30% cheaper than Amgen’s product and aims to capture significant share of the market.
India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push
MUMBAI - Many months after keeping its biosimilars plans under wraps, Cipla - India's second-largest drug maker - shared some parts of its proposed big picture that revolves around a manufacturing site in Goa, India, and another firm in Hong Kong that is putting up a biologics manufacturing facility in Shanghai